We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+4.97%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$484M
AUM Growth
+$61.6M
Cap. Flow
+$48.7M
Cap. Flow %
10.05%
Top 10 Hldgs %
47.59%
Holding
66
New
18
Increased
20
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.8M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.7M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$13.7M
4
FTD
FTD Companies, Inc. Common Stock
FTD
+$11.4M
5
VSTO
Vista Outdoor Inc.
VSTO
+$11.1M

Top Sells

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$12.9M
2
LVS icon
Las Vegas Sands
LVS
+$12.6M
3
CPB icon
Campbell Soup
CPB
+$9.55M
4
WFM
Whole Foods Market Inc
WFM
+$9.39M
5
URBN icon
Urban Outfitters
URBN
+$8.54M

Sector Composition

Rank Sector Weight
1 Healthcare 37.37%
2 Consumer Discretionary 21.51%
3 Consumer Staples 10.76%
4 Industrials 3.99%
5 Financials 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$66M 13.63%
280,000
+30,000
+12% +$6.97M
ATRS
2
DELISTED
Antares Pharma, Inc.
ATRS
$24.7M 5.1%
8,700,000
-2,300,000
-21% -$5.53M
VNDA icon
3
Vanda Pharmaceuticals
VNDA
$328M
$22.5M 4.65%
1,608,000
+1,028,000
+177% +$14.7M
WFM
4
CALL
DELISTED
Whole Foods Market Inc
WFM
$20.8M 4.3%
+700,000
New +$21.1M
NVLN
5
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$19.9M 4.11%
1,852,000
+432,000
+30% +$4.41M
FRPT icon
6
Freshpet
FRPT
$2.8B
$16.2M 3.35%
1,476,000
+60,000
+4% +$648K
REGN icon
7
Regeneron Pharmaceuticals
REGN
$71.2B
$15.5M 3.2%
+40,000
New +$14.8M
HAIN icon
8
Hain Celestial
HAIN
$52.5M
$15.2M 3.13%
408,000
+28,000
+7% +$1.05M
ADMS
9
DELISTED
Adamas Pharmaceuticals
ADMS
$15.1M 3.12%
864,000
+328,000
+61% +$5.59M
HBI
10
DELISTED
Hanesbrands
HBI
$14.5M 3%
700,000
+164,000
+31% +$3.48M
SGI
11
Somnigroup International
SGI
$15.8B
$13.8M 2.84%
1,184,000
+624,000
+111% +$8.02M
KATE
12
DELISTED
Kate Spade & Company
KATE
$13.3M 2.74%
572,000
+372,000
+186% +$7.78M
NOMD icon
13
Nomad Foods
NOMD
$1.64B
$12.9M 2.66%
1,124,000
+224,000
+25% +$2.39M
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
$12.9M 2.65%
+106,000
New +$13.7M
RXDX
15
DELISTED
Ignyta, Inc.
RXDX
$12.8M 2.64%
1,486,000
-514,000
-26% -$3.76M
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$12.6M 2.59%
850,000
+200,000
+31% +$3.24M
PII icon
17
Polaris
PII
$4.2B
$11.1M 2.28%
132,000
+62,000
+89% +$5.34M
SGYP
18
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$10.5M 2.17%
2,250,000
+550,000
+32% +$3.19M
DECK icon
19
Deckers Outdoor
DECK
$15.1B
$10.3M 2.12%
1,032,000
-312,000
-23% -$2.88M
FTD
20
DELISTED
FTD Companies, Inc. Common Stock
FTD
$10.1M 2.08%
+500,000
New +$11.4M
VSTO
21
DELISTED
Vista Outdoor Inc.
VSTO
$9.27M 1.91%
+450,000
New +$11.1M
AVDL
22
DELISTED
Avadel Pharmaceuticals
AVDL
$9.25M 1.91%
956,000
+128,000
+15% +$1.28M
PRKS icon
23
United Parks & Resorts
PRKS
$2.22B
$8.77M 1.81%
+480,000
New +$8.93M
ENTA icon
24
Enanta Pharmaceuticals
ENTA
$384M
$8.38M 1.73%
272,000
+44,000
+19% +$1.37M
SAM icon
25
Boston Beer
SAM
$1.9B
$7.81M 1.61%
54,000
+20,000
+59% +$3.13M
1
2 3

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Armistice Capital held 66 positions worth $484M, up 15% from $423M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Armistice Capital deployed $48.7M of net new capital in Q1 2017, opening 18 new positions and adding to 20 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 40,000 shares worth $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, up from 36% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was Aralez Pharmaceuticals Inc., an estimated $8.03M trimmed.

  • Armistice Capital's largest Q1 2017 buy was Regeneron Pharmaceuticals: 40,000 shares worth $15.5M.
  • Armistice Capital added most to Vanda Pharmaceuticals in Q1 2017, an estimated $14.7M increase.
  • Armistice Capital's biggest Q1 2017 reduction was Aralez Pharmaceuticals Inc., cutting an estimated $8.03M.
  • Armistice Capital fully exited Pacira BioSciences in Q1 2017, selling an estimated $12.9M.
  • Armistice Capital's ten largest holdings make up 48% of its $484M portfolio in Q1 2017.
  • Armistice Capital opened 18 new positions and closed 19 in Q1 2017.
  • Armistice Capital's portfolio value rose 15% quarter-over-quarter to $484M.

Based on Armistice Capital's 13F filing for Q1 2017, filed 15 May 2017.